Last reviewed · How we verify
NCT03660397
Adrenal Artery Ablation for Uncontrolled Hypertension
Phase 3 trial testing Selective endovascular chemical ablation of adrenal gland in Uncontrolled Hypertension in 40 participants. Status unknown.
1 July 2019
Quick facts
| Lead sponsor | Third Military Medical University |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 August 2018 |
| Primary completion | 1 July 2019 |
| Estimated completion | 1 January 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Selective endovascular chemical ablation of adrenal gland
- Traditional triple antihypertensive treatment — full drug profile →
Conditions studied
- Uncontrolled Hypertension — all drugs for Uncontrolled Hypertension →
Sponsor
Third Military Medical University
Who can join
Adults 30 to 60, any sex, with Uncontrolled Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The activation of the renin-angiotensin-aldosterone system (RAAS) plays a key role in uncontrolled hypertension or resistant hypertension. Surgery and and medicine are the main treatment for primary aldosteronism(PA) by the current guidelines. However, only a small part of patients with PA meet the surgical criteria, and most of patients with uncontrolled hypertension and activation of RAAS have to take spironolactone or other antihypertensive drugs for long time. On the other side, long-term inhibition of aldosterone receptor may cause hyperkalemia, male breast hyperplasia and other adverse reactions. Moreover, hyperaldosterone is still not corrected by spironolactone, which causes extensive cerebrovascular damages even though blood pressure and blood potassium had been normalized. With the development of adrenal vein sampling and adrenal ablation, selective arterial ablation of adrenal gland(AAA) was observed with significant decrease of blood aldosterone and blood pressure in patients with PA, which made it promising that uncontrolled hypertension could be relieved by selective AAA.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03660397
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Uncontrolled Hypertension
Currently open trials in the same condition.
- NCT07005050 — Renal Pelvic Denervation Pilot Trial · NA · recruiting
- NCT06610448 — Wearable Evaluation of Ambulatory Readings for Blood Pressure · NA · recruiting
- NCT06926855 — Community Health Workers Reduce Social Barriers That Affect the Health of Patients With High Blood Pressure and Diabetes · NA · active not recruiting
- NCT06344104 — A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or Mo · Phase 3 · active not recruiting
- NCT06938633 — Addressing Medication Non-adherence in Patients With Poorly Controlled Hypertension Using Urine Mass Spectrometry · NA · recruiting
Other Third Military Medical University trials
Trials by the same sponsor.
- NCT07536477 — High-flow Nasal Cannula Oxygen Therapy Versus Conventional Oxygen Therapy in High-altitude Pulmonary Edema · NA · not yet recruiting
- NCT07488507 — Diagnostic Value and Safety of Combined Biopsy for Mediastinal Metastasis of Lung Cancer · NA · recruiting
- NCT07277907 — Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation · Phase 3 · recruiting
- NCT04557995 — Erythrocytapheresis for Chronic Mountain Sickness · NA · recruiting
- NCT07036588 — PARLAR-02 Trial：Modified Transanal Drainage Tube Use for Preventing Anastomotic Leakage · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03660397 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Third Military Medical University
- Last refreshed: 6 September 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03660397.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing